# Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer

> **NCT00677924** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 9 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Zalutumumab

## Key facts

- **NCT ID:** NCT00677924
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to changes in portfolio review
- **Last updated:** 2023-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677924, "Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00677924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*